Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 6 clinical trials
Study of Efficacy and Safety of Valproic Acid in Chronic Lymphocytic Leukemia (CLL)

The purpose of this study is to determine whether Valproic acid, as a single agent is effective in the treatment of Chronic Lymphocytic Leukemia which has relapsed or is refractory to therapy with standard drugs.

cancer
lymphoid leukemia
neutrophil count
platelet count
nucleoside analog
  • 22 views
  • 07 Nov, 2020
  • 1 location
Natural Killer Cell (CYNK-001) Infusions in Adults With AML

This study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemotherapy. The safety of this treatment will be evaluated, and researchers want to learn …

cancer
hysterectomy
immunosuppressant
blast cells
immunosuppressive agents
  • 41 views
  • 11 Mar, 2021
  • 7 locations
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate COVID-19 disease.

cancer
hysterectomy
antibiotic therapy
ct scan
immunosuppressant
  • 141 views
  • 22 Mar, 2021
  • 9 locations
Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases

There is currently an urgent need for low cost and well tolerated intralesional agents for the management of in transit and cutaneous melanoma metastases that are unsuitable for, or resistant to, other therapies. This pilot study will determine whether intralesional injections of the sclerosant polidocanol into intransit and cutaneous melanoma …

metastasis
malignant melanoma of skin
melanoma skin
  • 0 views
  • 24 Jan, 2021
  • 1 location
Precision IFX: Using a Dashboard to Individualize Infliximab Dosage

The introduction of infliximab (IFX) and other monoclonal antibodies (MAbs) targeting tumor necrosis factor (TNF) was a major advancement in the management of inflammatory bowel disease (IBD). These biologics were able to improve the health outcomes of many IBD patients for whom other treatments were neither satisfactory nor sufficient. Despite …

tumor necrosis factor alpha
enteropathy
tumor necrosis factor
infliximab
  • 0 views
  • 28 Jan, 2021
  • 1 location
Functional Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia in Taiwan

Emerging results suggest that a cure rate of nearly 90 percent will be attained in the near future. The advance was attributed to stringent application of prognostic factors for risk factor-directed therapy. Early response to treatment has greater prognostic strength than does any other biologic or clinical feature tested to …

cancer
childhood all
lymphoid leukemia
minimal residual disease
residual tumor
  • 6 views
  • 07 Nov, 2020